GTB-3650 Tri-Specific Killer Engager (TriKE®)
HM2023-05: GTB-3650 (Anti-CD16/IL-15/Anti-CD33) Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML)
Near Add Your Location
Sorting 1 by
MDS Center of Excellence
A Center of Excellence as recognized by the MDS Foundation, is a hospital that has demonstrated its commitment to MDS research. This is accomplished by conducting specialized genetic testing, offering ongoing clinical trials for MDS patients, and actively participating in peer-reviewed MDS research.
University of Minnesota - Masonic Cancer Center
Minneapolis, MN
- Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.